selfworth10
Sophomore
@selfworth10
Posts: 416
Likes: 174
|
Post by selfworth10 on Aug 3, 2020 23:58:17 GMT
As many U.S. colleges plan to welcome back students this month, they face challenges unlike any other industry — containing the coronavirus among a young, carefree population that not only studies together, but also lives together, parties together and, if decades of history are any guide, sleeps together.
In one of the more elaborate plans, the University of California, Berkeley, will test all residential students within 24 hours of their arrival. After that, everyone living on campus will be tested twice a month if its test proves accurate enough.
But Cornell College in Iowa, with only 1,000 students, is counting on its humble health center and county health department to do its testing. Small schools in similar situations are finding themselves at the mercy of private labs that can take two weeks to deliver results, making results almost meaningless.
It is still possible that the frantic planning will come to naught.
|
|
selfworth10
Sophomore
@selfworth10
Posts: 416
Likes: 174
|
Post by selfworth10 on Aug 4, 2020 0:08:17 GMT
Coronavirus vaccines are rapidly advancing through the development pipeline. The University of Oxford’s vaccine is in large trials in Britain, Brazil and South Africa. In the United States, researchers just began enrolling around 30,000 volunteers to test Moderna’s vaccine, and more trials are starting every day. Operation Warp Speed has set an ambitious goal of delivering 300 million doses of a safe, effective vaccine by January.
But the concept of developing a vaccine at “warp speed” makes many people uncomfortable. In a May survey, 49 percent of the Americans polled said they plan to get a coronavirus vaccine when one is available, 20 percent do not, and 31 percent indicated that they were not sure. The World Health Organization considers “vaccine hesitancy” a major threat to global health, and poor uptake would jeopardize the impact of a coronavirus vaccine
The World Health Organization says a vaccine should be at minimum 50 percent effective, averaged across age groups. (We know from influenza that vaccines don’t always work as well on older adults whose immune systems have declined.)
This benchmark is crucial because a weak vaccine might be worse than no vaccine at all. We do not want people who are only slightly protected to behave as if they are invulnerable, which could exacerbate transmission. It is also costly to roll out a vaccine, diverting attention away from other efforts that we know work, like mask-wearing, and from testing better vaccines.
|
|